# Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma

> **NCT04339738** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 90 (actual)

## Conditions studied

- Skin Angiosarcoma
- Skin Radiation-Related Angiosarcoma
- Visceral Angiosarcoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cabozantinib S-malate
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** FDG-Positron Emission Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Paclitaxel
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT04339738
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-04
- **Primary completion:** 2025-03-30
- **Final completion:** 2027-01-21
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04339738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04339738, "Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT04339738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*